Guo J, Garratt A, Hill A. Worldwide rates of diagnosis and effective treatment for cystic fibrosis. J Cyst Fibros. 2022;21(3):456–62. https://doi.org/10.1016/j.jcf.2022.01.009.

Article  PubMed  Google Scholar 

Lopes-Pacheco M. CFTR modulators: shedding light on precision medicine for cystic fibrosis. Front Pharmacol. 2016;7:275.

Article  PubMed  PubMed Central  Google Scholar 

Heijerman HGM, McKone EF, Downey DG, VX17-445-103 Trial Group, et al. Efficacy and safety of the Elexacaftor plus Tezacaftor plus Ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019;394:1940–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yu E, Sharma S, Cystic Fibrosis. [Updated 2022 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK493206/

Shaughnessy CA, Zeitlin PL, Bratcher PE. Elexacaftor is a CFTR potentiator and acts synergistically with Ivacaftor during acute and chronic treatment [published correction appears in sci rep. 2021;11(1):21295]. Sci Rep. 2021;111:19810. https://doi.org/10.1038/s41598-021-99184-1. Published 2021 Oct 6.

Article  CAS  Google Scholar 

Keating C, Stefanie S et al. Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials. Lancet Respi Med, 13(3):256–71.

ClinicalTrials.gov. Available from: https://clinicaltrials.gov/study/NCT03525444. Registered on 2029-04-24.

8, Bacalhau M, Camargo M, Magalhães-Ghiotto GA, Drumond S, Castelletti CH, Lopes-Pacheco M. Elexacaftor-tezacaftor-ivacaftor: a life-changing triple combination of CFTR modulator drugs for cystic fibrosis. Pharmaceuticals. 2023;16(3):410.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gifford AH, Taylor-Cousar JL, Davies JC, McNally P. Update on clinical outcomes of highly effective modulator therapy. Clin Chest Med. 2022;43(4):677–95.

Article  PubMed  Google Scholar 

Bergeron C, Cantin AM. New therapies to correct the cystic fibrosis basic defect. Int J Mol Sci. 2021;22(12): 6193.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Taylor-Cousar JL, Robinson PD, Shteinberg M, Downey DG. CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis. Lancet. 2023;402(10408):1171–84.

Article  CAS  PubMed  Google Scholar 

Sutharsan S, McKone EF, Downey DG, Duckers J, MacGregor G, Tullis E, Van Braeckel E, Wainwright CE, Watson D, Ahluwalia N, et al. Efficacy and safety of Elexacaftor plus Tezacaftor plus Ivacaftor versus Tezacaftor plus Ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial. Lancet Respir Med. 2022;10:267–77. https://doi.org/10.1016/S2213-2600(21)00454-9.

Article  CAS  PubMed  Google Scholar 

European Medicines Agency. Kaftrio. [Internet]. 2020 Aug 28 [cited 2023 May 17]. Available: https://www.ema.europa.eu/en/documents/product-information/kaftrio-epar-product-information_pt.pdf

Vertex Pharmaceuticals Incorporated. TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor) [prescribing information]. Boston, MA: Vertex Pharmaceuticals Incorporated; 2019.

Google Scholar 

Middleton PG, Mall MA, Dřevínek P, Lands LC, McKone EF, Polineni D, et al. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med. 2019;381(19):1809–19.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med. 1999;340(1):23–30.

Article  CAS  PubMed  Google Scholar 

Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, et al. Effect of aerosolized Recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med. 1994;331(10):637–42.

Article  CAS  PubMed  Google Scholar 

Borowitz D, Grand RJ, Durie PR. Use of pancreatic enzyme supplements for patients with cystic fibrosis in the context of fibrosing colonopathy. J Pediatr. 1995;127(5):681–4.

Article  CAS  PubMed  Google Scholar 

Flume PA, O’Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ, Willey-Courand DB, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2007;176(10):957–69.

Article  CAS  PubMed  Google Scholar 

Elborn JS. Cystic fibrosis. Lancet. 2016;388(10059):2519–31.

Article  CAS  PubMed  Google Scholar 

Konstan MW, Morgan WJ, Butler SM, Pasta DJ, Craib ML, Silva SJ, et al. Risk factors for rate of decline in FEV1 in adults with cystic fibrosis. J Cyst Fibros. 2017;16(6):687–93.

Google Scholar 

U.S. Food and drug administration. FDA approves new breakthrough therapy for cystic fibrosis. FDA News Release. 2019.

Olesen HV, Orchard MA, Johansen HK, Pressler T. Cystic fibrosis related diabetes in adults. Diabetes Care. 2004;27(11):2702–8.

Google Scholar 

Heijerman HGM, McKone EF, Downey DG, Van Goor F, Higgins M, Keshavjee S, et al. Efficacy and safety of the Elexacaftor plus Tezacaftor plus Ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019;394(10212):1940–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Middleton PG, Mall MA, Dřevínek P, et al. Elexacaftor–Tezacaftor–Ivacaftor for cystic fibrosis with a single Phe508del mutation. N Engl J Med. 2019;381(19):1809–19.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Keating D, Marigowda G, Burr L, et al. VX-445-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles. N Engl J Med. 2018;379(17):1612–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sawicki GS, McKone EF, Pasta DJ, et al. Sustained benefit from Ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data. Am J Respir Crit Care Med. 2015;192(7):836–42.

Article  CAS  PubMed  Google Scholar 

Quinn M, Kosorok MR, Robinson W, et al. Economic evaluation of CFTR modulators for people with cystic fibrosis: A systematic review. J Cyst Fibros. 2020;19(6):871–9.

Google Scholar 

McKone EF, Ramos KJ, Sutharsan S, et al. Combination therapy for cystic fibrosis: effectiveness and safety of elexacaftor/tezacaftor/ivacaftor. Ther Clin Risk Manag. 2021;17:167–77.

Google Scholar 

Davies JC, Moskowitz SM, Brown C, et al. VX-659-Tezacaftor-Ivacaftor in patients with cystic fibrosis and one or two Phe508del mutations. N Engl J Med. 2018;379(17):1599–611.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zemanick ET, Taylor-Cousar JL, Davies J, et al. A phase 3 open-label study of elexacaftor/tezacaftor/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele. Am J Respir Crit Care Med. 2021;203(12):1522–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Graeber SY, Hug C, Sommerburg O, et al. Effects of elexacaftor/tezacaftor/ivacaftor therapy on young children with cystic fibrosis: a single-center experience. Pediatr Pulmonol. 2021;56(6):1831–5.

Google Scholar 

Moran A, Pillay K, Becker D, et al. Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review. Diabetes Care. 2010;33(12):2677–83.

Article  PubMed  PubMed Central  Google Scholar 

Mohan K, Israel KL, Miller MR, et al. CFTR modulator therapies: impact on glucose metabolism and implications for cystic fibrosis-related diabetes. J Cyst Fibros. 2021;20(2):230–6.

Google Scholar 

Boudreau V, Huot C, Retornaz F, et al. The impact of cystic fibrosis transmembrane conductance regulator (CFTR) modulators on cystic fibrosis-related diabetes: a systematic review. J Clin Endocrinol Metab. 2021;106(4):e1907–18.

Google Scholar 

Ciofu O, Tolker-Nielsen T, Jensen PØ, et al. Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients. Adv Drug Deliv Rev. 2015;85:7–23.

Article  CAS  PubMed  Google Scholar 

Taylor-Cousar JL, Jain M, Barto TL, et al. Pregnancy and neonatal outcomes of women with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor. J Cyst Fibros. 2021;20(3):424–30.

Google Scholar